Send the following on WhatsApp
Continue to ChatI liked this article on M3 India: Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: Subanalysis of the EMPA-REG OUTCOME randomised trial. Have a read: https://www.m3india.in/contents/journal/empagliflozin-reduces-cardiovascular-events?utm_campaign=unset&utm_medium=share&utm_source=ref_wa